ALBEY PAPER WASP VENOM (Polistes spp. venom) - Allergen (hymenoptera venoms)
Opinions on drugs -
Posted on
Jul 24 2025
Reason for request
Inclusion on list
Summary of opinion
Favourable opinion for reimbursement in “the diagnosis of hypersensitivity to Polistes spp. wasp venom and the treatment by allergen immunotherapy of subjects allergic to Polistes spp. wasp venom”.
Clinical Benefit
Substantial
The clinical benefit of ALBEY PAPER WASP VENOM (Polistes spp. venom) powder and solvent for solution for injection is substantial in the MA indications.
Clinical Added Value
no clinical added value
Considering:
the efficacy of allergen immunotherapy using hymenoptera venoms, including paper wasp venom, demonstrated by bibliographic data, with rates of protection against the development of systemic reactions following accidental or induced stings ranging from 89% to 100%,
the persistence of this efficacy, also documented in the literature, with protection rates of be tween 77% and 90% in adults 3 to 7 years after discontinuation of treatment, and up to 97% 10 to 20 years after discontinuation in children, but taking into account:
the low level of methodological evidence of the available studies, all including at least one major bias or limitation,
non-analysable exploratory quality of life data in a condition marked by a high level of anxiety related to the risk of getting stung again or recurrence of the allergy,
the Committee deems that ALBEY PAPER WASP VENOM (Polistes spp. venom) powder and solvent for solution for injection provides no clinical added value (CAV V) in the current care pathway.
Listen
